AtriCure (ATRC) CEO receives stock awards, uses shares to cover taxes

Rhea-AI Filing Summary

AtriCure, Inc. President and CEO Michael H. Carrel reported equity compensation and related tax withholding transactions in AtriCure common stock. On March 1, 2026, he acquired 68,618 shares through a restricted stock award under the AtriCure, Inc. 2023 Stock Incentive Plan, with one third of the shares vesting on each of the first, second, and third anniversaries of the grant date.

He also acquired 101,280 shares upon the vesting and release of a performance share award under the same 2023 plan, after the company performance goals and required service period were met. To cover tax withholding obligations from vesting awards, he transferred 72,777 shares back to the company at $31.26 per share, characterized as a tax-withholding disposition. After these direct transactions, he directly held 784,498 shares of common stock.

In addition, Form 4 reflects 9,310 shares held indirectly by his children and 2,250 shares held indirectly by his parents. A footnote states he disclaims beneficial ownership of these indirectly held securities, except to the extent of his pecuniary interest.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider CARREL MICHAEL H

Role President, CEO, & Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	68,618	$0.00	--
Grant/Award	Common Stock	101,280	$0.00	--
Tax Withholding	Common Stock	72,777	$31.26	$2.28M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 755,995 shares (Direct); Common Stock — 9,310 shares (Indirect, Held by reporting person's children)

Footnotes (1)

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant. The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met. The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award. The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARREL MICHAEL H

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OH 45040-9695

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO, & Director

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		68,618	A	$0(1)	755,995	D
Common Stock	03/01/2026		A		101,280	A	$0(2)	857,275	D
Common Stock	03/01/2026		F		72,777(3)	D	$31.26	784,498	D
Common Stock								9,310	I	Held by reporting person's children(4)
Common Stock								2,250	I	Held by reporting person's parents(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

2. The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

3. The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

4. The reporting person disclaims beneficial ownership of these securities, except as to his pecuniary interest therein.

Remarks:

	/s/ Michael H. Carrel	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AtriCure (ATRC) CEO Michael Carrel report on this Form 4?

Michael Carrel reported equity compensation grants and related tax withholding in AtriCure common stock. He received restricted and performance-based share awards and transferred shares back to the company to satisfy tax obligations arising from award vesting.

How many AtriCure (ATRC) shares were granted to the CEO on March 1, 2026?

On March 1, 2026, the CEO acquired 68,618 shares via a restricted stock award and 101,280 shares from a performance share award. Both awards were issued under the AtriCure, Inc. 2023 Stock Incentive Plan after meeting required conditions.

What is the vesting schedule for the new AtriCure CEO restricted stock award?

The 68,618-share restricted stock award vests in three equal installments. One third vests on each of the first, second, and third anniversaries of the March 1, 2026 grant date, assuming continued satisfaction of the award’s service-based requirements.

Why did the AtriCure CEO transfer 72,777 shares back to the company?

He transferred 72,777 shares back to AtriCure at $31.26 per share to cover tax withholding obligations. These obligations arose when restricted stock and performance share awards vested and were released, and the transaction is classified as a tax-withholding disposition.

How many AtriCure (ATRC) shares does the CEO own directly after these transactions?

After the reported award grants and tax-withholding disposition, Michael Carrel directly holds 784,498 shares of AtriCure common stock. This figure reflects his direct ownership only and excludes shares held indirectly by certain family members.

What indirect AtriCure share holdings related to the CEO are disclosed on this Form 4?

The filing notes 9,310 AtriCure shares held by the CEO’s children and 2,250 shares held by his parents. A footnote states he disclaims beneficial ownership of these indirectly held securities, except to the extent of any pecuniary interest he may have.